Clough Rachel E, Martin-Gonzalez Teresa, Van Calster Katrien, Hertault Adrien, Spear Rafaëlle, Azzaoui Richard, Sobocinski Jonathan, Haulon Stéphan
Aortic Center, Hôpital Cardiologique, CHRU de Lille, Lille, France.
Aortic Center, Hôpital Cardiologique, CHRU de Lille, Lille, France.
Ann Vasc Surg. 2017 Oct;44:158-163. doi: 10.1016/j.avsg.2017.05.013. Epub 2017 May 22.
Prophylactic open surgery is the standard practice in patients with connective tissue and thoracoabdominal aortic aneurysm (TAAA) and aortic arch disease. Branched and fenestrated devices offer a less invasive alternative but there are concerns regarding the durability of the repair and the effect of the stent graft on the fragile aortic wall. The aim of this study is to evaluate mid-term outcomes of fenestrated and/or branched endografting in patients with connective tissue disease.
All patients with connective tissue disease who underwent TAAA or arch aneurysm repair using a fenestrated and/or branched endograft in a single, high-volume center between 2004 and 2015 were included. Ruptured aneurysms and acute aortic dissections were excluded from this study, but not chronic aortic dissections.
In total, 427 (403 pararenal and TAAAs, and 24 arch aneurysms) endovascular interventions were performed during the study period. Of these, 17 patients (4%) (16 TAAAs, 1 arch) had connective tissue disease. All patients were classified as unfit for open repair. The mean age was 51 ± 8 years. Thirteen patients with TAAA were treated with a fenestrated, 1 with a branched, and 2 with a combined fenestrated/branch device. A double inner branch device was used to treat the arch aneurysm. The technical success rate was 100% with no incidence of early mortality, spinal cord ischemia, stroke, or further dissection. Postoperative deterioration in renal function was seen in 3 patients (18.8%) and no hemodialysis was required. The mean follow-up was 3.4 years (0.3-7.4). Aneurysm sac shrinkage was seen in 35% of patients (6/17) and the sac diameter remained stable in 65% of patients (11/17). No sac or sealing zone enlargement was observed in any of the patients and there were no conversions to open repair. Reintervention was required in 1 patient at 2 years for bilateral renal artery occlusion (successful fibrinolysis). One type II endoleak (lumbar) is under surveillance and 1 type III (left renal stent) sealed spontaneously. One patient died at 2 years after the procedure from nonaortic causes (endocarditis).
The favorable mid-term outcomes in this series that demonstrate fenestrated and/or branched endografting should be considered in patients with connective tissue and TAAA and aortic arch disease, which are considered unfit for open surgery. All patients require close lifetime surveillance at a center specializing in aortic surgery, with sufficient experience in both open and endovascular aortic surgery, so that if endovascular treatment failure occurs it can be recognized early and further treatment offered.
预防性开放手术是患有结缔组织病、胸腹主动脉瘤(TAAA)和主动脉弓疾病患者的标准治疗方法。分支型和开窗型器械提供了一种侵入性较小的替代方案,但对于修复的耐久性以及支架移植物对脆弱主动脉壁的影响仍存在担忧。本研究的目的是评估开窗型和/或分支型血管腔内修复术在结缔组织病患者中的中期疗效。
纳入2004年至2015年间在单一高容量中心接受开窗型和/或分支型血管腔内修复术治疗TAAA或主动脉弓瘤的所有结缔组织病患者。本研究排除破裂性动脉瘤和急性主动脉夹层,但慢性主动脉夹层除外。
在研究期间共进行了427例血管腔内干预(403例肾旁和TAAA,以及24例主动脉弓瘤)。其中,17例患者(4%)(16例TAAA,1例主动脉弓)患有结缔组织病。所有患者均被归类为不适合开放修复。平均年龄为51±8岁。13例TAAA患者接受了开窗型治疗,1例接受了分支型治疗,2例接受了开窗/分支联合装置治疗。使用双内分支装置治疗主动脉弓瘤。技术成功率为100%,无早期死亡、脊髓缺血、中风或进一步夹层的发生。3例患者(18.8%)术后肾功能恶化,无需血液透析。平均随访时间为3.4年(0.3 - 7.4年)。35%的患者(6/17)动脉瘤囊缩小,65%的患者(11/17)囊直径保持稳定。所有患者均未观察到瘤囊或密封区扩大,也没有转为开放修复。1例患者在2年后因双侧肾动脉闭塞需要再次干预(成功溶栓)。1例II型内漏(腰动脉)正在监测中,1例III型(左肾支架)自行封闭。1例患者在术后2年因非主动脉原因(心内膜炎)死亡。
本系列中显示开窗型和/或分支型血管腔内修复术具有良好中期疗效,对于被认为不适合开放手术的结缔组织病、TAAA和主动脉弓疾病患者应予以考虑。所有患者都需要在专门从事主动脉手术且在开放和血管腔内主动脉手术方面均有足够经验的中心进行终身密切监测,以便在血管腔内治疗失败时能够早期识别并提供进一步治疗。